Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + thalidomide
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Irinotecan + thalidomide is an investigational combination therapy consisting of two small molecule drugs, irinotecan and thalidomide. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication in cancer cells, leading to cell death. Thalidomide acts primarily as an antiangiogenic agent by inhibiting the formation of new blood vessels that supply tumors, and also has immunomodulatory properties. This combination has been studied in clinical trials for various advanced solid tumors, including recurrent glioblastoma multiforme (GBM), metastatic colorectal cancer, and recurrent central nervous system (CNS) tumors. The rationale for combining these agents is to enhance antitumor efficacy by targeting both tumor cell proliferation (irinotecan) and tumor vasculature (thalidomide)[1][2][3][4][5].
- Other names
- irinotecan + thalidomide
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + thalidomide.